Biogen Applies for FDA Approval of Hemophilia Med

Jan 4, 2013, 08:00 AM by Michael Croft

News Brief | Biogen Idec has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of a treatment for hemophilia B.

January 4, 2013 | Biogen Idec has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of a treatment for hemophilia B. The regulatory submission was based on results from B-LONG, the largest registrational phase 3 clinical study in hemophilia B to date. Biogen Idec Press Release